Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Cdc20 CRISPR/Cas9 KO Plasmid (h): sc-400583
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Cdc20 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Cdc20 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Cdc20 Antibody (E-7): sc-13162
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdc20 CRISPR/Cas9 KO Plasmid (h) | sc-400583 | 20 µg | $397.00 |
Overview
CDC20 encodes Cdc20, an essential co-activator of the anaphase-promoting complex/cyclosome (APC/C) that controls the metaphase-to-anaphase transition by promoting ubiquitin-dependent degradation of key mitotic regulators. Its activity is regulated by the spindle assembly checkpoint through inhibitory complexes with proteins such as MAD2 and BUBR1, ensuring accurate chromosome segregation and timely mitotic exit. CDC20 dysregulation perturbs checkpoint fidelity, drives chromosomal instability and aneuploidy, and is frequently linked to proliferative phenotypes in cancer biology. As a central node in cell-cycle governance, Cdc20 is commonly studied in pathways involving APC/C signaling, ubiquitin–proteasome dynamics, and mitotic checkpoint control.
Cdc20 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CDC20 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CDC20 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CDC20 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Cdc20 protein expression.
This CRISPR knockout system enables efficient generation of CDC20-deficient cell models for investigation of Cdc20 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CDC20 exon(s) critical for Cdc20 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CDC20 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Cdc20 CRISPR/Cas9 KO Plasmid (h) and Cdc20 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CDC20 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Cdc20 HDR Plasmid (h) and Cdc20 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CDC20 homology arms to support homology-directed repair at defined CDC20 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.